Tensions have run high in the multidistrict litigation over Boehringer Ingelheim GmbH’s drug Pradaxa, to the point where Boehringer once sought a court order barring plaintiffs counsel from harassing company employees during depositions. But with a bellwether trial approaching, the legal teams have put aside their resentments and worked out a comprehensive settlement.
Boehringer announced Wednesday that it’s paying $650 million to settle about 4,000 personal injury lawsuits relating to Pradaxa, a blood thinner alleged to have caused bleed-out deaths among patients. Those cases were consolidated into an MDL before U.S. District Judge David Herndon in East St. Louis, Ill. The first trial was scheduled for September.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
